Japan's development of oral vaccine for early-onset dementia will be conducted in human clinical trials

Japanese scientists have developed an oral vaccine for Alzheimer's disease, which has been proven to be therapeutic and safe in mice, Singapore's Union Morning Post reportedTian Pingwu, director of the National Institute of Longevity in Aichi Prefecture in central Honshi, Japan, said yesterday that the team could conduct small-scale clinical trials in humans this year"We hope to successfully complete the first phase of the experiment, " Tian saidAnimals can recover when they develop symptoms, but humans have poor healing, perhaps only when the initial symptoms are mild"
the study group gave the mice the vaccine, the brain amyloid plaque decreased and the intelligence improvedThe medical community believes that amyloid plaques are the scourge of Alzheimer's diseaseAlzheimer's disease, commonly known as early-onset dementia, is currently incurableThe ageing of people around the world has made this dementia a growing social problemFive million people in the United States suffer from the diseaseTian Pingwu pointed out that oral vaccine will not cause inflammation or bleeding in the mouse brainHe said the team injected a harmless virus that makes starch into a virus that, after feeding the vaccine, attacks and breaks down starch proteins in the brainThe team first modified the genes of 28 mice to develop Alzheimer's disease, and then treated themHalf of the mice were vaccinated at 10 months of age, while the other half of the control group did not take the drugAfter three months, the experiment showed that the mental function of the sick mice taking the drug was almost restored to its pre-disease statusU.S drugmaker Wyeth and its Irish partner, Ilan, have developed an ACC-001 vaccine for trials to treat patients with Alzheimer's disease (rereproduced from "China News Network")